ExonHit Therapeutics

ExonHit files patent on a panel of genes for the diagnosis of Alzheimer disease from blood

Published in Lab Law Weekly, June 23rd, 2006

ExonHit Therapeutics, a drug and diagnostic discovery company, announced that it has filed a patent with the French Intellectual Property Institute (INPI) which covers a panel of genes that could enable the differential diagnosis of Alzheimer patients from blood.

The use of these genes will allow the identification of patients suffering from Alzheimer disease from a population of elderly patients with no signs of cognitive disorders.

This is an important development as there is currently no diagnostic test that can accurately identify patients with Alzheimer disease. The diagnosis of Alzheimer disease is determined by default after an in-depth...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2006-06-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry